Report Detail

Request for Sample of this report

Pharma & Healthcare Global Radioligand Therapy Drugs Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

  • RnM4665615
    • |
  • 19 January, 2026
    • |
  • Global
    • |
  • 122 Pages
    • |
  • GIR
    • |
  • Pharma & Healthcare

According to our (Global Info Research) latest study, the global Radioligand Therapy Drugs market size was valued at US$ 3247 million in 2025 and is forecast to a readjusted size of US$ 5444 million by 2032 with a CAGR of 7.8% during review period.
In 2025, global Radioligand Therapy Drugs reached approximately 76.49 K Units, with an average global market price of around 41254 USD per Unit.
Radioligand Therapy (RLT) drugs are targeted radiopharmaceutical cancer medicines that pair a tumor-seeking “ligand” (targeting molecule) with a therapeutic radioactive isotope (radionuclide). After intravenous administration, the ligand binds to a specific target on (or in) cancer cells, and the radionuclide delivers cell-killing radiation locally, aiming to limit exposure to surrounding healthy tissue.
Radioligand therapy (RLT) drugs combine the precision of targeted medicine with the cell-killing power of radiation, delivering a therapeutic payload directly to tumors based on a molecular marker rather than just anatomy, which helps address several long-standing pain points in oncology: limited efficacy after multiple lines of treatment, high systemic toxicity from broadly acting drugs, and the need for better patient selection to avoid costly trial-and-error care. By pairing a targeting ligand with a therapeutic radioisotope, RLT can concentrate dose where disease is active—including small or disseminated lesions—while often remaining compatible with existing imaging workflows and multidisciplinary cancer care, making outcomes more predictable and enabling clearer treatment sequencing. Industry momentum is being driven by a convergence of factors: rapid growth in biomarker-guided oncology, rising unmet need in hard-to-treat metastatic disease, increasing confidence from real-world clinical adoption, and meaningful investment in isotope supply, manufacturing capacity, and specialized treatment infrastructure that reduces earlier bottlenecks. Looking ahead, the market potential is reinforced by a deepening pipeline across multiple tumor types and targets, next-generation isotopes and chemistries that may improve tumor penetration and durability, and expanding global capacity that can progressively normalize availability; as these elements mature, RLT is positioned to evolve from a niche option into a more routine modality that complements—and in some settings competes with—established systemic therapies, shaping a long runway for growth without relying on hype.
Radioligand Therapy Drugs' upstream raw materials mainly include therapeutic radionuclides, targeted ligands, and excipients. Typical suppliers include ITM, Curium, SHINE Technologies, and NRG. Downstream applications primarily involve the treatment of cancers such as prostate cancer, liver cancer, breast cancer, and lung cancer.
The production capacity of a single Radioligand Therapy Drugs production line is affected by the supply of radionuclides, synthesis efficiency, equipment configuration, and quality control standards. Significant differences exist between different drugs and production lines. Radioligand Therapy Drugs' gross profit margin ranges from 70% to 80%.
This report is a detailed and comprehensive analysis for global Radioligand Therapy Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Radioligand Therapy Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Radioligand Therapy Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Radioligand Therapy Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Radioligand Therapy Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Radioligand Therapy Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Radioligand Therapy Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Bayer, Progenics (Lantheus), Acrotech Biopharma Inc, BMS, AstraZeneca, Eli Lilly, Convergent Therapeutics, Grand Pharmaceutical, Bivision Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Radioligand Therapy Drugs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Lutetium 177
Radium 223
Acetium 225
Others
Market segment by Targeted Ligands
by Peptides
Small Molecules
Antibodies
Others
Market segment by Radionuclides
β-emitters
α-emitters
Others
Market segment by Application
Prostate Cancer
Liver Cancer
Breast Cancer
Lung Cancer
Others
Major players covered
Novartis
Bayer
Progenics (Lantheus)
Acrotech Biopharma Inc
BMS
AstraZeneca
Eli Lilly
Convergent Therapeutics
Grand Pharmaceutical
Bivision Pharmaceuticals
Jiangsu Hengrui
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Radioligand Therapy Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Radioligand Therapy Drugs, with price, sales quantity, revenue, and global market share of Radioligand Therapy Drugs from 2021 to 2026.
Chapter 3, the Radioligand Therapy Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Radioligand Therapy Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Radioligand Therapy Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Radioligand Therapy Drugs.
Chapter 14 and 15, to describe Radioligand Therapy Drugs sales channel, distributors, customers, research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Radioligand Therapy Drugs Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Lutetium 177
    • 1.3.3 Radium 223
    • 1.3.4 Acetium 225
    • 1.3.5 Others
  • 1.4 Market Analysis by Targeted Ligands
    • 1.4.1 Overview: Global Radioligand Therapy Drugs Consumption Value by Targeted Ligands: 2021 Versus 2025 Versus 2032
    • 1.4.2 by Peptides
    • 1.4.3 Small Molecules
    • 1.4.4 Antibodies
    • 1.4.5 Others
  • 1.5 Market Analysis by Radionuclides
    • 1.5.1 Overview: Global Radioligand Therapy Drugs Consumption Value by Radionuclides: 2021 Versus 2025 Versus 2032
    • 1.5.2 β-emitters
    • 1.5.3 α-emitters
    • 1.5.4 Others
  • 1.6 Market Analysis by Application
    • 1.6.1 Overview: Global Radioligand Therapy Drugs Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.6.2 Prostate Cancer
    • 1.6.3 Liver Cancer
    • 1.6.4 Breast Cancer
    • 1.6.5 Lung Cancer
    • 1.6.6 Others
  • 1.7 Global Radioligand Therapy Drugs Market Size & Forecast
    • 1.7.1 Global Radioligand Therapy Drugs Consumption Value (2021 & 2025 & 2032)
    • 1.7.2 Global Radioligand Therapy Drugs Sales Quantity (2021-2032)
    • 1.7.3 Global Radioligand Therapy Drugs Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Novartis
    • 2.1.1 Novartis Details
    • 2.1.2 Novartis Major Business
    • 2.1.3 Novartis Radioligand Therapy Drugs Product and Services
    • 2.1.4 Novartis Radioligand Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Novartis Recent Developments/Updates
  • 2.2 Bayer
    • 2.2.1 Bayer Details
    • 2.2.2 Bayer Major Business
    • 2.2.3 Bayer Radioligand Therapy Drugs Product and Services
    • 2.2.4 Bayer Radioligand Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Bayer Recent Developments/Updates
  • 2.3 Progenics (Lantheus)
    • 2.3.1 Progenics (Lantheus) Details
    • 2.3.2 Progenics (Lantheus) Major Business
    • 2.3.3 Progenics (Lantheus) Radioligand Therapy Drugs Product and Services
    • 2.3.4 Progenics (Lantheus) Radioligand Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Progenics (Lantheus) Recent Developments/Updates
  • 2.4 Acrotech Biopharma Inc
    • 2.4.1 Acrotech Biopharma Inc Details
    • 2.4.2 Acrotech Biopharma Inc Major Business
    • 2.4.3 Acrotech Biopharma Inc Radioligand Therapy Drugs Product and Services
    • 2.4.4 Acrotech Biopharma Inc Radioligand Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Acrotech Biopharma Inc Recent Developments/Updates
  • 2.5 BMS
    • 2.5.1 BMS Details
    • 2.5.2 BMS Major Business
    • 2.5.3 BMS Radioligand Therapy Drugs Product and Services
    • 2.5.4 BMS Radioligand Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 BMS Recent Developments/Updates
  • 2.6 AstraZeneca
    • 2.6.1 AstraZeneca Details
    • 2.6.2 AstraZeneca Major Business
    • 2.6.3 AstraZeneca Radioligand Therapy Drugs Product and Services
    • 2.6.4 AstraZeneca Radioligand Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 AstraZeneca Recent Developments/Updates
  • 2.7 Eli Lilly
    • 2.7.1 Eli Lilly Details
    • 2.7.2 Eli Lilly Major Business
    • 2.7.3 Eli Lilly Radioligand Therapy Drugs Product and Services
    • 2.7.4 Eli Lilly Radioligand Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Eli Lilly Recent Developments/Updates
  • 2.8 Convergent Therapeutics
    • 2.8.1 Convergent Therapeutics Details
    • 2.8.2 Convergent Therapeutics Major Business
    • 2.8.3 Convergent Therapeutics Radioligand Therapy Drugs Product and Services
    • 2.8.4 Convergent Therapeutics Radioligand Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Convergent Therapeutics Recent Developments/Updates
  • 2.9 Grand Pharmaceutical
    • 2.9.1 Grand Pharmaceutical Details
    • 2.9.2 Grand Pharmaceutical Major Business
    • 2.9.3 Grand Pharmaceutical Radioligand Therapy Drugs Product and Services
    • 2.9.4 Grand Pharmaceutical Radioligand Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Grand Pharmaceutical Recent Developments/Updates
  • 2.10 Bivision Pharmaceuticals
    • 2.10.1 Bivision Pharmaceuticals Details
    • 2.10.2 Bivision Pharmaceuticals Major Business
    • 2.10.3 Bivision Pharmaceuticals Radioligand Therapy Drugs Product and Services
    • 2.10.4 Bivision Pharmaceuticals Radioligand Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Bivision Pharmaceuticals Recent Developments/Updates
  • 2.11 Jiangsu Hengrui
    • 2.11.1 Jiangsu Hengrui Details
    • 2.11.2 Jiangsu Hengrui Major Business
    • 2.11.3 Jiangsu Hengrui Radioligand Therapy Drugs Product and Services
    • 2.11.4 Jiangsu Hengrui Radioligand Therapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Jiangsu Hengrui Recent Developments/Updates

3 Competitive Environment: Radioligand Therapy Drugs by Manufacturer

  • 3.1 Global Radioligand Therapy Drugs Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Radioligand Therapy Drugs Revenue by Manufacturer (2021-2026)
  • 3.3 Global Radioligand Therapy Drugs Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Radioligand Therapy Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Radioligand Therapy Drugs Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Radioligand Therapy Drugs Manufacturer Market Share in 2025
  • 3.5 Radioligand Therapy Drugs Market: Overall Company Footprint Analysis
    • 3.5.1 Radioligand Therapy Drugs Market: Region Footprint
    • 3.5.2 Radioligand Therapy Drugs Market: Company Product Type Footprint
    • 3.5.3 Radioligand Therapy Drugs Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Radioligand Therapy Drugs Market Size by Region
    • 4.1.1 Global Radioligand Therapy Drugs Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Radioligand Therapy Drugs Consumption Value by Region (2021-2032)
    • 4.1.3 Global Radioligand Therapy Drugs Average Price by Region (2021-2032)
  • 4.2 North America Radioligand Therapy Drugs Consumption Value (2021-2032)
  • 4.3 Europe Radioligand Therapy Drugs Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Radioligand Therapy Drugs Consumption Value (2021-2032)
  • 4.5 South America Radioligand Therapy Drugs Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Radioligand Therapy Drugs Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Radioligand Therapy Drugs Sales Quantity by Type (2021-2032)
  • 5.2 Global Radioligand Therapy Drugs Consumption Value by Type (2021-2032)
  • 5.3 Global Radioligand Therapy Drugs Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Radioligand Therapy Drugs Sales Quantity by Application (2021-2032)
  • 6.2 Global Radioligand Therapy Drugs Consumption Value by Application (2021-2032)
  • 6.3 Global Radioligand Therapy Drugs Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Radioligand Therapy Drugs Sales Quantity by Type (2021-2032)
  • 7.2 North America Radioligand Therapy Drugs Sales Quantity by Application (2021-2032)
  • 7.3 North America Radioligand Therapy Drugs Market Size by Country
    • 7.3.1 North America Radioligand Therapy Drugs Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Radioligand Therapy Drugs Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Radioligand Therapy Drugs Sales Quantity by Type (2021-2032)
  • 8.2 Europe Radioligand Therapy Drugs Sales Quantity by Application (2021-2032)
  • 8.3 Europe Radioligand Therapy Drugs Market Size by Country
    • 8.3.1 Europe Radioligand Therapy Drugs Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Radioligand Therapy Drugs Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Radioligand Therapy Drugs Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Radioligand Therapy Drugs Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Radioligand Therapy Drugs Market Size by Region
    • 9.3.1 Asia-Pacific Radioligand Therapy Drugs Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Radioligand Therapy Drugs Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Radioligand Therapy Drugs Sales Quantity by Type (2021-2032)
  • 10.2 South America Radioligand Therapy Drugs Sales Quantity by Application (2021-2032)
  • 10.3 South America Radioligand Therapy Drugs Market Size by Country
    • 10.3.1 South America Radioligand Therapy Drugs Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Radioligand Therapy Drugs Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Radioligand Therapy Drugs Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Radioligand Therapy Drugs Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Radioligand Therapy Drugs Market Size by Country
    • 11.3.1 Middle East & Africa Radioligand Therapy Drugs Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Radioligand Therapy Drugs Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Radioligand Therapy Drugs Market Drivers
  • 12.2 Radioligand Therapy Drugs Market Restraints
  • 12.3 Radioligand Therapy Drugs Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Radioligand Therapy Drugs and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Radioligand Therapy Drugs
  • 13.3 Radioligand Therapy Drugs Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Radioligand Therapy Drugs Typical Distributors
  • 14.3 Radioligand Therapy Drugs Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Radioligand Therapy Drugs. Industry analysis & Market Report on Radioligand Therapy Drugs is a syndicated market report, published as Global Radioligand Therapy Drugs Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Radioligand Therapy Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,690.04
    		4,035.06
    		5,380.08
    		3,239.88
    		4,859.82
    		6,479.76
    		531,361.20
    		797,041.80
    		1,062,722.40
    		293,712.00
    		440,568.00
    		587,424.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo